Ugne Zekonyte News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ugne zekonyte. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ugne Zekonyte Today - Breaking & Trending Today

Precision BioSciences Announces New Study Published in Nature Communications Using Engineered ARCUS Nuclease to Target Mutant Mitochondrial DNA In Vivo

Published: Jun 01, 2021
June 1, 2021 11:00 UTC
Learnings to be Presented by Carlos Moraes, Ph.D., from University of Miami at UMDF’s Mitochondrial Medicine Symposium on June 4, 2021
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and
in vivo gene correction therapies with its ARCUS® genome editing platform, today announced a new paper published online in
Nature Communications that reports
preclinical results using an ARCUS nuclease to target mitochondrial DNA (mtDNA) and reduce levels of mutant mtDNA
in vivo.
The study, “Mitochondrial targeted meganuclease as a platform to eliminate mutant mtDNA in vivo” was led by Carlos T. Moraes, Ph.D., Esther Lichtenstein Professor in Neurology at the University of Miami Miller School of Medicine, with Ugne Zekonyte as first author. ....

United States , Ugne Zekonyte , Carlost Moraes , Derek Jantz , Precision Biosciences Inc , Nature Communications , Virtual Meet The Scientific Program Faculty On , United Mitochondrial Disease Foundation Medicine , University Of Miami Miller School Medicine , Esther Lichtenstein Professor , Miami Miller School , Chief Scientific Officer , United Mitochondrial Disease Foundation , Mitochondrial Medicine , Scientific Program , Precision Biosciences , Private Securities Litigation Reform Act , Quarterly Report , Recent Advances , Annu Rev Genomics Hum Genet , Recision Biosciences Announces New Study Published In Nature Communications Using Engineered Arcus Nuclease To Target Mutant Mitochondrial Dna Vivo , ஒன்றுபட்டது மாநிலங்களில் , டெரெக் ஜந்தஜ் , ப்ரிஸிஶந் உயிர் அறிவியல் இன்க் , இயற்கை தகவல்தொடர்புகள் , பல்கலைக்கழகம் ஆஃப் மியாமி மில்லர் பள்ளி மருந்து ,

Precision BioSciences Announces New Study Published in Nature Communications Using Engineered ARCUS

Search jobs
01-Jun-2021
Precision BioSciences Announces New Study Published in Nature Communications Using Engineered ARCUS Nuclease to Target Mutant Mitochondrial DNA In Vivo

Learnings to be Presented by Carlos Moraes, Ph.D., from University of Miami at UMDF’s Mitochondrial Medicine Symposium on June 4, 2021
DURHAM, N.C. (BUSINESS WIRE) Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and
in vivo gene correction therapies with its ARCUS® genome editing platform, today announced a new paper published online in
Nature Communications that reports
preclinical results using an ARCUS nuclease to target mitochondrial DNA (mtDNA) and reduce levels of mutant mtDNA ....

United States , University Of Miami , Ugne Zekonyte , Alex Kelly , Carlos Moraes , Carlost Moraes , Derek Jantz , Precision Biosciences Inc , Nature Communications , Virtual Meet The Scientific Program Faculty On , United Mitochondrial Disease Foundation Medicine , University Of Miami Miller School Medicine , Medicine Symposium , Precision Biosciences , Esther Lichtenstein Professor , Miami Miller School , Chief Scientific Officer , United Mitochondrial Disease Foundation , Mitochondrial Medicine , Scientific Program , Private Securities Litigation Reform Act , Quarterly Report , Recent Advances , Annu Rev Genomics Hum Genet , ஒன்றுபட்டது மாநிலங்களில் , பல்கலைக்கழகம் ஆஃப் மியாமி ,

Study reports positive preclinical results for Precision Biosciences ARCUS® technology

by WRAL TechWire June 1, 2021 .
DURHAM – Applications of the ARCUS® genome editing platform, a proprietary technology from Durham-headquartered Precision BioSciences, were studied in research now published online by Nature Communications. The study demonstrated the technology may be used to edit outside of the nuclear genome.
The paper, “Mitochondrial targeted meganuclease as a platform to eliminate mutant mtDNA in vivo” was led by Carlos T. Moraes, Ph.D., Esther Lichtenstein Professor in Neurology at the University of Miami Miller School of Medicine, with Ugne Zekonyte as first author, reports preclinical results using an ARCUS nuclease to target mitochondrial DNA (mtDNA) and reduce levels of mutant mtDNA in vivo. ....

United States , Ugne Zekonyte , Carlost Moraes , Derek Jantz , Nature Communications , University Of Miami Miller School Medicine , Durham Headquartered Precision Biosciences , Esther Lichtenstein Professor , Miami Miller School , Chief Scientific Officer , Precision Biosciences , Alex Kelly , Chief Financial Officer , ஒன்றுபட்டது மாநிலங்களில் , டெரெக் ஜந்தஜ் , இயற்கை தகவல்தொடர்புகள் , பல்கலைக்கழகம் ஆஃப் மியாமி மில்லர் பள்ளி மருந்து , மியாமி மில்லர் பள்ளி , தலைமை அறிவியல் அதிகாரி , ப்ரிஸிஶந் உயிர் அறிவியல் , அலெக்ஸ் கெல்லி , தலைமை நிதி அதிகாரி ,